The Ten-Eleven-Translocation 2 (TET2) gene has recently been implicated in a variety of hematopoietic malignancies in adults. Mutations and deletions were detected in myelodysplastic syndromes, acute myeloid leukemias (AML) and other myeloid malignancies. [1] [2] [3] [4] [5] So far, however, the presence of TET2 mutations has not been reported in childhood leukemia.
Precursor B-cell acute lymphoblastic leukemia (ALL) and AML represent the most frequently occurring hematopoietic malignancies in children. During the past decades, the survival rates of children with these malignancies have improved Letters to the Editor considerably, but a substantial subset of the patients still suffers from relapses and treatment-related mortality. Genetic abnormalities may provide insights into the mechanisms underlying the etiology of leukemia and the development of therapy resistance. In addition, they may provide novel clues for the development of targeted therapies. TET2 mutations are found in 8-19% of adult AML, 1, 5 and the expression of TET2 is high in granulocytes as compared with other hematopoietic and non-hematopoietic cells, where it is increased during myeloid differentiation.
1 Also normal B-cells show high TET2 expression, 1 but TET2 mutations in adult ALL have not been reported. Here, we set out to assess a cohort of childhood AMLs and precursor B-cell ALLs for the presence of mutations in TET2.
In total, 104 childhood AML and 47 childhood precursor B-cell ALL cases were included in this study. All patient material was obtained with informed consent through the Dutch Childhood Oncology Group. Patient characteristics are listed in Supplementary Table 1. DNA was isolated from peripheral blood or bone marrow cells at diagnosis. Sequence analysis was carried out bidirectionally as reported before using primers covering all exons of the TET2 gene, including its intron-exon boundaries. 1 All sequence variations were confirmed independently. In order to establish whether the observed mutations were acquired, DNA from remission material was analyzed whenever available. All sequence variations were compared with those published in the literature and listed in public databases.
Novel TET2 mutations were detected in 4 of the 104 AML samples tested (3.8%, 95% confidence interval 1.6-8.2%) ( Figure 1a , Table 1 ). In addition, 16 single-nucleotide polymorphisms (SNPs) were found, some of which have not been reported before (Figure 1a) . One of the patients, a 3-month old girl (UPN AML51), suffered from AML-M0. A conversion of cytosine to guanine at position 1526 of the TET2 gene led to the formation of a premature stop codon. A second patient, a 17-year old boy (UPN AML60), suffered from AML-M2. In his case, the TET2 mutation (c.3001A4T) gave rise to a premature stop codon as well. In both cases the mutations were not detected in DNA obtained during remission. Both premature stop codons were located in the N-terminal moiety of the protein, upstream of the two conserved domains BOX1 and BOX2 (Figure 1a) . The two other patients with TET2 mutations suffered from AML-M4. In one of them, a 14-year old girl (UPN AML07), the mutation (c.1379C4T) led to a conversion of a serine to a phenylalanine, again upstream of the two conserved domains in the protein. Unfortunately, remission DNA from this patient was not available for analysis, but literature and database searches revealed that this mutation has been reported before and was shown to be acquired. 5 In the fourth patient, the diagnosis sample showed a homozygous mutation of one basepair upstream of the GT-splice-donor site of intron 5. This mutation, an insertion of a thymine, was absent in remission material (Figure 2a) . In addition to the mutation, we detected two SNPs, which were homozygous in the diagnosis sample, but heterozygous in the remission sample (Figure 2a) , indicative for the presence of either a deletion or a region of acquired uniparental disomy affecting the TET2 gene. Subsequent SNP array-based genomic profiling of the respective DNA samples indeed confirmed the presence of an acquired uniparental disomy of the long arm of chromosome 4 harboring the TET2 gene (Figure 2b ). This patient also carried an NPM1 and a FLT3 ITD mutation (Table 1) which, together with the fact that TET2 expression is increased during myeloid differentiation, 1 may suggest that TET2 abnormalities should be considered as type II mutations.
No TET2 mutations were found in the precursor B-cell ALL cohort (Figure 1b) . The locations of 14 TET2 SNPs are depicted in Figure 1b . In two patients we detected sequence variations leading to amino-acid substitutions in the isoform 2 of TET2. Remission material of these patients was not available for analysis, but considering the fact that these variations only affect the short TET2 isoform lacking the two conserved domains BOX1 and BOX2, we consider that the functional consequences of these variations may be limited. One of the variations (p.Gly1160Glu) was also encountered in a cohort of adult AML patients (our unpublished results), and was found to be present in remission material. Therefore, we conclude that this variation represents a SNP.
Compared with adult AML, 1,5 the incidence of TET2 mutations in childhood AML seems to be lower (8-19% versus 3.8%). In adult AML, TET2 mutations appear to correlate with a poor prognosis 5 (own unpublished results). As yet, however, this childhood AML cohort is too small to draw any firm conclusion on its prognostic implications.
In our precursor B-cell ALL cohort no TET2 mutations were found. Previously, we and others performed SNP array-based analyses on precursor B-cell ALLs 6,7 and identified recurrent deletions, duplications and acquired uniparental disomies affecting various regions on the genome, but the 4q24 region encompassing the TET2 gene was not affected. 
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The mechanism by which TET2 mutations contribute to the etiology of myeloid malignancies is, as yet, poorly understood. Tahiliani et al. 8 have implicated that the TET2 homolog TET1 may be involved in epigenetic gene regulation. Specifically, they found that TET1 has a role in the transition of 5-methylcytosine to 5-hydroxymethylcytosine. Very recently TET2 was reported to possess similar enzymatic activity. 9 In conclusion, we have detected novel TET2 mutations in 3.8% of pediatric AML. Despite the lower incidence compared with lateonset AML, this observation may be instrumental for the design of novel targeted therapies in pediatric acute myeloid leukemia. 

